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doi: 10.1016/j.exphObjective. The molecular mechanisms that maintain human pluripotent stem (PS) cells are
not completely understood. Here we sought to identify new candidate PS cell regulators to
facilitate future improvements in their generation, expansion, and differentiation.
Materials and Methods. We used bioinformatic analyses of multiple serial-analysis-of-gene-
expression libraries (generated from human PS cells and their differentiated derivatives),
together with small interfering RNA (siRNA) screening to identify candidate pluripotency
regulators. Validation of candidate regulators involved promoter analyses, Affymetrix
profiling, real-time PCR, and immunoprecipitation.
Results. Promoter analysis of genes differentially expressed across multiple serial-analysis-of-
gene-expression libraries identified E2F motifs in the promoters of many PS cell-specific genes
(e.g., POU5F1, NANOG, SOX2, FOXD3). siRNA analyses identified two retinoblastoma
binding proteins (RBBP4, RBBP9) as required for maintenance of multiple human PS cell
types. Both RBBPs were bound to RB in human PS cells, and E2F motifs were present in
the promoters of genes whose expression was altered by decreasing RBBP4 and RBBP9
expression. Affymetrix and real-time PCR studies of siRNA-treated human PS cells showed
that reduced RBBP4 or RBBP9 expression concomitantly decreased expression of POU5F1,
NANOG, SOX2, and/or FOXD3 plus certain cell cycle genes (e.g., CCNA2, CCNB1), while
increasing expression of genes involved in organogenesis (particularly neurogenesis).
Conclusions. These results reveal new candidate positive regulators of human PS cells,
providing evidence of their ability to regulate expression of pluripotency, cell cycle, and differ-
entiation genes in human PS cells. These data provide valuable new leads for further eluci-
dating mechanisms of human pluripotency.  2011 ISEH - Society for Hematology and
Stem Cells. Published by Elsevier Inc.Given appropriate physiologic stimulation, human pluripo-
tent stem (PS) cells can differentiate into every cell typebertson, Delaney, Morozova, Poon and Yap contrib-
ork.
: Michael D. O’Connor, Ph.D., University of Western
1797, Penrith, NSW, Australia, 2751.; E-mail: m.
associated with this article can be found in the
1016/j.exphem.2011.05.008.
nt matter. Copyright  2011 ISEH - Society for Hematol
em.2011.05.008found in the body. Moreover, if kept under appropriate
laboratory conditions, human PS cells can retain this latent
developmental potential while proliferating rapidly. Great
strides have been made in recent years in our understanding
of the molecular mechanisms responsible for human PS cell
self-renewal and differentiation, but additional knowledge
is essential to increasing the efficiency with which pluripo-
tent human cells can be generated and expanded. These
issues, in turn, are prerequisite to using human PS cells
for realizing anticipated advances in human developmental
biology, biotechnology, and medicine.ogy and Stem Cells. Published by Elsevier Inc.
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mechanisms that maintain the status of human PS cells
is based on studies of POU5F1, NANOG, SOX2, and
FOXD3. These four transcription factors are believed to
act as a self-reinforcing autoregulatory network that simul-
taneously suppresses the expression of genes required for
differentiation [1–6]. The central role that these four factors
play in maintaining PS cells has also led to their broad use
as markers of the pluripotent state, thereby enabling refine-
ment of conditions for human PS cell maintenance.
POU5F1 expression, in particular, has been widely used
for this purpose. Along with other genes such as SOX2,
NANOG, KLF4, and c-MYC, POU5F1 has also proven to
be a key element in protocols for reprogramming somatic
cells to a pluripotent state [7–9]. However, most of these
genes have also been found to be replaceable, reflecting
the complexity and redundancy that exist in the cell
signaling pathways involved in maintaining PS cells in an
undifferentiated state. For example, Nr5a2 has been shown
to be capable of replacing Pou5f1 for the reprogramming of
mouse cells [10]. Similarly, omitting cMYC from the reprog-
ramming cocktail reduces the generation of induced PS
(iPS) cells with tumorigenic properties, but at the expense
of reprogramming efficiency [11]. Taken together, these
studies underscore the need for more detailed understanding
of the genes involved in human PS cell maintenance to
enable further exploitation of the multiple opportunities
that human PS cells offer.
A variety of human PS cells exist, including human
embryonal carcinoma (EC) cells [2,12], embryonic stem
(ES) cells [13], and iPS cells [7–9]. Human ES and iPS
cells are the most likely PS cell types to have clinical
applications, however, human EC cells have for almost
3 decades provided a useful model to study pluripotency,
as they are more easily propagated and genetically modi-
fied, yet possess similar properties to ES and iPS cells [12].
In the present study, we used examples of each of these
three human PS cell types to look for novel regulators of
human pluripotency. As a first step, we looked for shared
transcription factor binding sequences in the promoter
regions of genes that we found were expressed in undiffer-
entiated human ES and EC cells [14]. These studies sug-
gested the family of E2F transcription factors to be likely
candidate regulators of many human PS cell-specific genes.
In parallel, we undertook experiments to screen small
interfering RNA (siRNAs) for elements that would inhibit
the rapid proliferation of human EC cells as a surrogate
indicator of a loss of their pluripotent status. From this latter
study, we identified 23 genes (6 known, 17 novel), including
the gene encoding the retinoblastoma (RB)-binding protein,
RBBP9, as candidate pluripotency regulators. Subsequent
experiments indicated that both RBBP9 and another RB-
binding protein (RBBP4) appear to play similar, but not
identical, roles in maintaining human EC, ES, and iPS cell
pluripotency.Materials and methods
Cells
H9 human ES cells were purchased from WICELL (Madison, WI,
USA) and NTera2D1 human EC cells were obtained from the
ATCC (Manassas, VA, USA). The CA1 human ES cells were
provided by A. Nagy [15] and MSC-iPSC1 human iPS cells
were provided by G. Daley [8]. Approval for use of these cells
as described was obtained from the Canadian Stem Cell Oversight
Committee and the Research Ethics Board of the University of
British Columbia.Cell culture, colony assay, and flow cytometry
The H9 human ES cells used to generate the novel Tag-Seq
serial analysis of gene expression (SAGE) libraries hs0212,
hs0046, and hs0048 were maintained using mouse embryonic
fibroblasts using media containing Knock-Out Serum Replacer
(Invitrogen, Carlsbad, CA, USA) and 10 ng/mL FGF 2 (StemCell
Technologies, Vancouver, BC, Canada) as described previously
[16]. All other human ES and iPS cell cultures were maintained
in mTeSR1 (StemCell Technologies) [16]. Human EC cells
were passaged every 3 or 4 days using TrypLE (Invitrogen),
and plated on tissue culture plastic in DS medium consisting of
Dulbecco’s modified Eagle’s medium (StemCell Technologies)
containing 10% fetal bovine serum (StemCell Technologies).
For bulk differentiation cultures using all-trans retinoic acid
(RA; Sigma, St Louis, MO, USA), the medium was replaced
with DS medium supplemented with 105 M RA, and cells were
cultured for at least 4 days with medium changes as necessary.
Alkaline phosphatase-based colony-forming cell (CFC) assays
were performed as described previously [16]. Consistent with
previously published results, no alkaline phosphatase-negative
colonies were seen in any of the assays.
Flow cytometric assessment of SSEA3þ cells was performed
using an anti-SSEA3 antibody (Developmental Studies Hybridoma
Bank, Iowa City, IA, USA) and a fluorescein isothiocyanate
conjugated anti-mouse IgM secondary antibody (Becton
Dickinson, San Jose, CA, USA). Data was collected using
a FACSCalibur (Becton Dickinson) and analyzed using FlowJo
software (Tree Star, Ashland, OR, USA) as described previously
[17]. Gates for positive cells were set to excludeO99% of events
detected when the primary antibody was omitted from the stain-
ing protocol.Gene expression profiling, PASTAA analysis, and GO analysis
LongSAGE [18] and Tag-Seq SAGE [19] gene expression libraries
were prepared as described previously. Tag-Seq libraries were pro-
cessed to filter out the majority of error tags using an analysis of
the frequency of one-off tags and mapping to genome and tran-
scriptome resources [19]. The libraries used are available via the
Gene Expression Omnibus database as part of record GSE14 of
the Cancer Genome Anatomy Project resource [20] as follows:
she10, HES3 human ES cells; she11, HES4 human ES cells;
she13, H7 human ES cells; she14, H14 human ES cells; she15,
H13 human ES cells; she16, H1 human ES cells; she17, H1
human ES cells; she19, BG01 human ES cells; shes2, H9 human
ES cells; shes9, HSF6 human ES cells; shs11, H1 human
ES cell-derived erythromegakaryocytic progenitors; shs12, H1
human ES cell-derived enriched primitive hematopoietic
868 M.D. O’Connor et al./ Experimental Hematology 2011;39:866–879multipotent progenitors; shs13, H1 human ES cell-derived en-
riched primitive hematopoietic myeloid progenitors; cg643,
normal adult bulk pancreas; cg647, mammary gland antibody
purified; cg648, normal substantia nigra; cg655, normal liver
vascular endothelium.
LongSAGE tags were mapped to genes using the SAGE Genie
tool. The resulting dataset was subjected to seriation analysis as
described [21]. To identify transcription factor binding sites in
groups of genes, we used the PASTAA Web server [14], which
ranks genes by estimating the overall affinity of a position weight
matrix (PWM) for sequence regions that are defined relative to the
transcriptional start site of each gene in a list. Gene ontology (GO)
analysis was performed using the program DAVID Bioinformatics
Suite [22].
For Affymetrix profiling, 12 samples (3 RBBP4 and 3 B2M
harvested 72 hours after siRNA treatment; plus 3  RBBP9 and
3  B2M harvested 48 hours after siRNA treatment) were analyzed
using HuGene 1.0 st arrays (Affymetrix, Santa Clara, CA, USA).
Labeling and hybridization to the arrays was performed by the
Ramaciotti Centre for Gene Function Analysis (University of
New South Wales, Sydney, Australia) as per manufacturer’s
instructions. Analysis of the resulting data was performed using
the GenePattern software suite [23], with the top 10% of up- and
down-regulated genes shown.
siRNA transfection
Single cell suspensions were plated into 96-well plates for siRNA
screens (Greiner, Frickenhausen, Germany) and 6-well plates
(Becton Dickinson) for Western blotting analyses, using a medium
appropriate for the cell type being evaluated (i.e., mTeSR1, DS
medium, or DS þ 105 M RA). Cells were allowed to attach over-
night before being transfected for 18 to 24 hours using Dharma-
Fect3 (DF3; Dharmacon, Lafayette, CO, USA) and Dharmacon
siGENOME siRNA at the concentration indicated. For the 319
gene-siRNA screens, triplicate test wells distributed over three
separate 96-well plates were used for each treatment, and each
treatment consisted of equimolar pools of four siRNAs per gene.
For follow-up studies, we used either equimolar pools of four
siRNA for each gene, or a combination of the two most effective
siRNAs for each gene. After transfection the medium was re-
placed with a cell-appropriate medium and the cells cultured for
an additional 2 to 3 days before final assessment. To approximate
the cell output, wells were stained with 1 mg/mL Hoechst 33342
(Sigma) and the fluorescence intensity of each well was measured
using a plate reader. Positive-effect control conditions (i.e.,
POU5F1 and NANOG siRNAs), as well as negative-effect control
conditions (i.e., B2M siRNAs or DF3 reagent only), were included
in each plate along with the test siRNAs to monitor for consistency
in relative response and to correct for plate-to-plate variations.
Two methods were used to infer cell densities from the fluores-
cence intensity values: traditional data normalization [24] and
linear modeling [25], as described here.
Normalization of siRNA screen data
For traditional normalization of the data [24], the background fluo-
rescence level obtained from unstained wells or stained wells
without added cells was first subtracted from the fluorescence
values of all other wells for each plate. The base 2 logarithm of
these background corrected values was then calculated to compen-
sate for variations expected in exponentially increasing numbersand, thus, obtain a more representative measure for each siRNA
over the different ranges of response evaluated. To compensate
for plate-to-plate variations, the median log value for the DF3
reagent-only control wells was subtracted from the log values
of all the wells. This resulted in the normalized value for the
DF3-only control wells being close to zero, and enabled the
normalized value for each siRNA-treated well to indicate the
relative effect on cell number. Comparisons of significance in
response to siRNA treatments against the B2M siRNA-negative
control wells were then made using a single-tailed t-test. A further
adjustment to the set of p-values for the 26 siRNA targets was
made to control for the false discovery rate that can arise by
chance from multidata comparisons [24].
For assessing the data using a linear model method, we first
log-transformed the measured values, as this gave the most
uniform and least residual error distribution for the model esti-
mate. The linear model includes a predictor random variable to
compensate for experiment-to-experiment effects, and another
predictor random variable to compensate for plate-to-plate differ-
ences in the plate-reader’s (optimal) gain settings used to capture
the fluorescence measurements. For each siRNA treatment, we ob-
tained a model estimate of its relative response versus the control
B2M siRNA wells in the same plate [25]. We then performed an
analysis of variance of the linear modeled data with a model where
the targeted siRNA does not have a different response from the
B2M test siRNA (the null hypothesis). Finally, the set of p values
for the 26 siRNA targets from the analysis of variance tests was
adjusted to control for the false discovery rate that can arise by
chance from multidata comparisons [24]. The rank ordering of
the siRNAs with respect to the relative response for both the
linear and traditional normalization methods are very similar:
i.e., siRNAs that exhibited a large differential response in the
linear model also exhibited a large difference in the traditional
normalization method. The results from the linear model are
reported here.
RNA purification and reverse transcription
RNA was extracted and purified using Absolutely RNA kits
(Stratagene, Cedar Creek, TX, USA). Reverse transcription using
Superscript II (Invitrogen) and quantitative real-time PCR using
Sybr-Green (Applied Biosystems, Warrington, WA, USA) was per-




AA, CTCCAGGTTGCCTCTCACTC); NANOG (AACTGGCC
GAAGAATAGCAA, CATCCCTGGTGGTAGGAAGA); SOX2
(CATGGCAATCAAAATGTCCA, TTTCACGTTTGCAACTGT
CC); FOXD3 (CAACCGCTTCCCCTACTACA, TTGACGAAGC
AGTCGTTGAG); B2M (GAATTCACCCCCACTGAAAA, CGA
GACATGTAAGCAGCATCA); RBBP4 (GTTGATGCTCACACT
GCTGAA, GATCCCACAAGGCAACAGTC); and RBBP9 (ACA
TCAGACTTGGGGGATGA, GGGTCGTCAGTAGAGCCAAA).Protein sample preparation, coimmunoprecipitation,
and Western blotting
Cells were collected using TrypLE for 10 minutes, centrifuged,
and the pellets washed with phosphate-buffered saline (StemCell
Technologies) before being resuspended in protein lysis buffer
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mM Na3VO4, 2 mM EDTA, 2 mM NaMoO4.2H2O, 10% glycerol,
2 mM PMSF (Sigma), 0.1% NP-40 alternative (Calbiochem,
Gibbstown, NJ, USA), and protease inhibitors (Sigma). For co-
immunoprecipitation, w300 mg of protein lysate was incubated
on a rocker overnight at 4C with either anti-human RB antibody
(Becton Dickinson) or Ig control antibody (Dako, Glostrup,
Denmark). Protein-G agarose beads (Thermo Fisher Scientific,
Rockford, IL, USA) were washed in protein lysis buffer, added
to each sample, and incubated on a rocker for 2 hours at 4C.
Samples were then centrifuged and the beads washed using protein
lysis buffer. Proteins were eluted by incubating for 10 minutes in
NuPAGE sample buffer/reducing agent (Invitrogen) at 95C before
Western analysis. For Western blotting, samples were separated on
4% to 12% NuPAGE Bis-Tris gels (Invitrogen), transferred to
PVDF membrane (Millipore, Billerica, MA, USA), blocked in
phosphate-buffered saline containing 0.1% Tween-20 (Sigma)
and 5% bovine serum albumin (Invitrogen), then incubated over-
night with one of the following anti-human antibodies: anti-RB
(Becton Dickinson), anti-RBBP4 (Bethyl Laboratories, Montgom-
ery, TX, USA), anti-RBBP9 (ProteinTech, Chicago, IL, USA), or
anti-GAPDH (Sigma). Blots were scanned to file using a Canon
Pixma MP160 digital scanner (Canon, Ontario, Canada) and are pre-
sented without digital manipulation. Densitometric analysis ofFigure 1. Biologic characterization of human PS cell SAGE libraries. (ALE) Fl
human ES cells (ALD) and NTera2D1 EC cells (E). (F) Alkaline phosphatase C
type and frequency comparisons for the Tag-Seq SAGE libraries generated here
libraries (G), as well as LongSAGE libraries used for seriation analysis (H).Western blots was performed using an LAS-4000 (FujiFilm Corpo-
ration, Tokyo, Japan) and accompanying Image Reader LAS-4000
software, and the levels of RBBP4 and RBBP9 protein compared
between siRNA treatments relative to GAPDH protein levels.
Statistical analyses
Tests for statistical significance were performed using the single-
tailed two-sample t-test, single-tailed paired two-sample t-test, or
analysis of variance, as appropriate. Statistical significance was
assigned to p values !0.05.Results
Comparative analyses of gene expression libraries
prepared from human PS cells
Three new Tag-Seq SAGE libraries were generated as
described previously [19] from undifferentiated human
H9 ES cells (p41; Fig. 1A, C; hs0046); undifferentiated
NTera2D1 human EC cells (Fig. 1E; hs0212); and from
human H9 ES cells (p41) harvested 96 hours after addition
of RA to induce their differentiation (Fig. 1B, D; hs0048).
Confirmation of the respective undifferentiated andow cytometry data for undifferentiated (A, C, E) and RA-treated (B, D) H9
FC frequencies for the same human ES cells shown in (ALD). (G, H) Tag
(hs0212, hs0046, hs0048) versus previously established LongSAGE meta-
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lished by flow cytometric analyses and assays for alkaline
phosphatase-positive CFCs performed as described previ-
ously [16]. These studies showed that most of the undiffer-
entiated H9 and NTera2D1 cells expressed high levels of
SSEA3 and/or POU5F1 (Fig. 1A, C, E), whereas most of
the RA-treated H9 cells expressed undetectable or much
lower levels of these antigens (Fig. 1B, D). The frequency
of CFCs in the H9 human ES cells was also greatly dimin-
ished (22-fold) in the RA-treated H9 cells (Fig. 1F).
These three Tag-Seq SAGE libraries were sequenced to
a depth that yielded between 4 and 13  106 total tags
that mapped to the human genome, and are included in
the Gene Expression Omnibus database as part of record
GSE14 of the Cancer Genome Anatomy Project resource
[20]. The Table in Supplementary Table E1 [online only,
available at www.exphem.org] shows a summary of the
tag frequencies for POU5F1, NANOG, SOX2, and FOXD3
by comparison to previously published values for LongS-
AGE libraries prepared from H9 and other undifferentiated
human ES cell lines [26]. The absolute level of tags for these
four pluripotency genes in the Tag-Seq libraries is up to 80-
fold higher than in the published LongSAGE libraries. We
then compared the frequencies and distribution of other
tags in the Tag-Seq SAGE libraries with data from equiva-
lently sized meta-libraries generated in silico from the pub-
lished LongSAGE data sets (obtained from nonpluripotent
as well as pluripotent cell populations; Fig. 1G). This
comparison showed the tag representation in the two new
undifferentiated human PS cell Tag-Seq SAGE libraries re-
ported here (hs0046 and hs0212) to be highly correlated,
both with each other and with the tags in the undifferentiated
human ES cell LongSAGE meta library.
The depth of the three Tag-Seq SAGE libraries made it
possible to identify 319 genes whose transcripts were present
at various levels in the Tag-Seq libraries prepared from
both of the undifferentiated cell types (see Supplementary
Table E2; online only, available at www.exphem.org). These
319 genes have been previously found to be involved in
transcription, chromatin maintenance, and membrane
receptor signaling.Use of seriation to identify developmentally restricted
gene subsets
As a first approach to identifying which of the 319 genes
might be most tightly linked to the maintenance of pluripo-
tency, we undertook a further analysis of their representation
in 17 previously published LongSAGE libraries prepared
from human cells that span a broad time course of develop-
ment. These additional libraries were derived from H9 and
other human ES cells before and after induction of their
differentiation, as well as various cell populations from
several adult human tissues (total 5 17 libraries; Fig. 1H).
For this analysis, we employed a heuristic approach (termedseriation) that identifies groups of genes with similar
expression levels in different libraries (termed Supercontigs)
[21] from pair-wise correlations of tag frequencies in the
libraries analyzed. We thus identified three Supercontigs
(see Supplementary Table E3; online only, available at
www.exphem.org). One contained 114 genes whose expres-
sion was mostly highly restricted to undifferentiated human
ES cells (Supercontig 1, Fig. 2A). This group contained tags
for POU5F1, NANOG, SOX2, and FOXD3 and other genes
whose expression is known to decrease upon human ES cell
differentiation. The average level of expression of these 114
genes in all 17 LongSAGE libraries is shown in Figure 2B.
A second group (Supercontig 2) consisted of 145 genes
whose expression was generally higher in differentiated
cells. The third subset (Supercontig 3) contained the remain-
ing 60 genes whose expression patterns did not fit within
either of the first two groups.
Identification of E2F motifs in promoters of genes
expressed in human PS cells
We then used PASTAA software to analyze the promoters
of the genes contained in these three Supercontigs, to
look for transcription factors that might participate in regu-
lating their expression [14]. PASTAA interrogates groups of
coexpressed genes and ranks their likelihood of being regu-
lated by a previously established transcription factor PWM.
Two separate PASTAA analyses were performed on each of
the three Supercontigs. One involved interrogating a region
extending 10-kb upstream from the transcription start site
(distal analysis); the other interrogated a region 6400 bp
on each side of the transcription start site (proximal anal-
ysis). In assessing the results obtained, we took into consid-
eration the fact that the PWM-based motif identification
method may not distinguish between specific members of
transcription factor families that bind to the same sequence,
even though this methodology may reliably identify
a common binding site shared by members of a particular
transcription factor family.
PASTAA analysis of Supercontig 1 (i.e., the undifferen-
tiated human PS cell-specific genes) showed SOX (p 5
0.0018) and FOX (p 5 0.041) PWMs to be highly ranked
in the distal analysis, and NANOG (p 5 0.013) and OCT/
POU (p 5 0.024) PWMs to be highly ranked in the prox-
imal analysis (Fig. 2C, D; also see Supplementary Table
E4; online only, available at www.exphem.org). Notably,
the PASTAA data predicted binding of these four core plu-
ripotency transcription factors to their own and each others’
promoters (see Supplementary Table E4; online only, avail-
able at www.exphem.org), as expected [27]. PASTAA anal-
ysis of Supercontig 2 also predicted a FOX motif to be
present in the distal promoter region of these genes (p 5
0.0185) and a NANOG motif in the proximal promoter
region (p 5 0.00786; see Supplementary Table E4; online
only, available at www.exphem.org). Analysis of Supercon-
tig 3 predicted FOX motifs in both the distal (p 5 0.0404)
Figure 2. Analysis of differentially expressed genes and bioinformatic identification of E2F transcription factors as regulators in human PS cells.
(A) Seriation analysis revealing three Supercontigs of co-expressed genes. (B) Average expression level for Supercontig1 genes across 17 previously estab-
lished LongSAGE libraries. (C, D) Proximal and distal promoter analyses for Supercontig1 genes [multiple ATF motifs are identified in (D)].
871M.D. O’Connor et al./ Experimental Hematology 2011;39:866–879and proximal (p5 0.0327) promoter regions of these genes,
but no NANOG, OCT/POU, or SOX motifs in either the
distal or proximal promoter regions (see Supplementary
Table E4; online only, available at www.exphem.org).
The demonstrated ability of the PASTAA analyses
to identify known transcriptional regulators of human
PS cells (i.e., NANOG, POU5F1, SOX2, and FOXD3),
encouraged us to investigate other novel candidates identi-
fied in the same analyses. E2F and ATF transcription
factors were among the top rankings in both the distal
and proximal promoter regions of genes in Supercontig 1
(see Supplementary Table E4; online only, available at
www.exphem.org). ATF PWMs were ranked 1st and 4th
in the distal analysis (p 5 0.0014 and 0.0046) and 21st in
the proximal analysis (p 5 0.029), while E2F PWMs were
ranked 21st in the distal analysis (p 5 0.045) and 22nd in
the proximal analysis (p 5 0.032). Notably, E2F and ATF
binding sites were found in the promoters of NANOG,
POU5F1, SOX2, and FOXD3 (see Supplementary TableE4; online only, available at www.exphem.org). Analysis
of Supercontig 2 revealed E2F (p 5 0.0324), but not ATF,
motifs in the distal promoter regions of these genes and
both E2F (p 5 0.00138 to 0.0449) and ATF (p 5 0.0465)
motifs in the proximal promoter regions. For Supercontig 3,
no evidence of either E2F or ATF motifs in the distal
promoter regions was found, but E2F (p 5 0.0373) and
ATF (p 5 0.000819 to 0.0431) motifs were present in the
proximal promoter regions.
An analysis of published chromatin-immunoprecipitation
(ChIP) data generated using antibodies against E2F1, E2F4,
and E2F6 provided further evidence that these transcription
factors are bound to the promoters of active genes in human
PS cells [28]. The ChIP data showed that the promoters of
NANOG, POU5F1, SOX2, and FOXD3 were all variably en-
riched in bound E2F1, E2F4, and E2F6 in NTera2 EC cells,
but this was not the case for any of the four nonpluripotent
cell lines analyzed in the same way (see Supplementary
Table E5; online only, available at www.exphem.org).
872 M.D. O’Connor et al./ Experimental Hematology 2011;39:866–879A similar ChIP experiment performed on undifferentiated
human ES cells [27] showed E2F4 bound to the promoter
of FOXD3 (see Supplementary Table E5; online only, avail-
able at www.exphem.org). Taken together, these findings
strongly suggested a role for E2Fs in regulating human
PS cells.
Identification of RBBPs as candidate regulators of
human PS cells
As a complementary approach to the identification of candi-
date regulators of human PS cells, we undertook a knock-
down screen using siRNAs for each of the 319 genes
initially identified from the Tag-Seq libraries (Fig. 3A).
We chose the NTera2D1 human EC cells to evaluate the
effects of these siRNAs because these cells share morpho-
logical, phenotypic, molecular, and functional propertiesFigure 3. Identification of genes involved in NTera2D1 cell maintenance. (A)
screens, and the re-screening of the 26 preliminary hits. siRNA effects were det
4 days after siRNA treatment, in comparison to the negative control (B2M siRNA
investigation of the 26 preliminary hits (3 experiments, 3 replicates/experiment:
treatment. POU5F1 and NANOG have more than nine wells, as these were used a
siRNAs tested in (B). Most show decreases of O50%. Data shown as mean 6with human ES and iPS cells [2,12], but are much easier
to genetically manipulate. To detect an altered pluripotent
state, we used Hoechst staining to measure the number of
cells present in triplicate cultures 4 days after the addition
of the siRNAs at a final concentration of 50 nM. This surro-
gate biological end point was chosen based on the assump-
tion that loss of essential pluripotency maintenance factors
would cause a marked and immediate prolongation of the
cell cycle transit time, or detachment, and/or death of tar-
geted cells. Support for this assumption was provided by
the prior successful application of a similar end point to
identify eight new pluripotency regulators in a RNA inter-
ference screen of mouse ES cells [29]. Preliminary experi-
ments using positive control siRNAs (against the known
pluripotency regulators NANOG and POU5F1), as well as
negative control siRNAs (against B2M that does not regulateDiagram of the siRNA screening strategy used for the 319-gene siRNA
ermined through measurement of cell numbers (via Hoechst fluorescence)
). (B) Rank ordering of the linear modeled data obtained from siRNA-based
þ, D, x). Each data point with the corresponding mean is shown for each
s positive controls in each experiment. (C) Reduction of transcript levels by
standard error of mean.
873M.D. O’Connor et al./ Experimental Hematology 2011;39:866–879pluripotency), demonstrated the specificity that could be ex-
pected using this approach. These preliminary experiments
also made it possible to optimize the reagent concentrations
and exposure times used.
Two initial experiments were performed with siRNAs
against all 319 genes (see Supplementary Figure E1; online
only, available at www.exphem.org). The results identified
26 preliminary hits. These hits were then rescreened in
another three experiments, at which stage the level of
siRNA-mediated mRNA transcript downregulation was as-
sessed. Most of these 26 siRNA treatments specifically
decreased messenger RNA levels from the target gene
by $50% (Fig. 3C), and 23 of the 26 also significantly
reduced the number of cells present after 4 days below
that measured in control cells treated with siRNAs against
B2M (Fig. 3B). The 23 confirmed hits are known to be
involved in regulating a range of biological processes,
including transcription (ASH2L, FOXH1, SALL4, ZIC3,
NANOG, SOX2, HMGA1, POU5F1, NR5A2); cell cycle
progression (SYCP3, PTTG1, CDC2 BIRC5, RBBP9);
signal transduction (CRABP1, GABRB3, IAPP); and
apoptosis (BIRC5, IAPP, CDC2).
One of the genes whose inhibited expression was
associated with the largest reduction of NTera2D1 cell
maintenance was the RB-binding protein, RBBP9. This
observation was of particular interest given that RB is
a well-established binding partner and regulator of E2F
transcription factor activity [30]. In addition, our PASTAA
analyses had identified E2F transcription factors as poten-
tial regulators of gene expression in PS cells. Interestingly,
re-examination of the H9 human ES cell Tag-Seq SAGE
libraries showed little change in RBBP9 expression
following induction of differentiation by exposure to RA.
However, another RB-binding protein (RBBP4) was found
to be expressed at a five-fold higher level in the undifferen-
tiated H9 cells as compared to their differentiating
derivatives.
siRNA-mediated loss of RBBPs induces changes
in human PS cell functional properties
These findings prompted us to design a further series of
experiments to investigate the potential role of RBBP4
and/or RBBP9 in human PS cell maintenance. As a first
step, we asked whether the findings obtained in NTera2D1
EC cells would be replicated in human ES and iPS cells.
Accordingly, we transiently transfected all three cell types
with siRNAs for B2M, RBBP4, and RBBP9 and then exam-
ined the amount of protein and total cells present 4 days
later. Western blots showed RBBP4 and RBBP9 were
specifically and consistently decreased across all 3 human
PS cell types in response to the appropriate siRNA treat-
ment (Figs. 4A, 5A). For the Western blots shown, densi-
tometry revealed an average decrease of 60% in RBBP9
protein levels (p 5 0.017) and 30% in RBBP4 protein
levels (p 5 0.004), relative to protein levels in the samecells treated with B2M siRNA, across all three human PS
cell types. This decrease in RBBP4 and RBBP9 protein
levels was also accompanied by a significant decrease in
the number of cells present 4 days after siRNA exposure
(Figs. 4B, 5B). siRNA-mediated inhibition of RBBP9 also
reduced the yield of cells in RA-differentiated derivatives
obtained from each of the cell types tested (Fig. 4B),
whereas loss of RBBP4 had little or no effect on these
RA-differentiated cells (Fig. 5B). This latter finding is
consistent with the observation that RBBP4, but not
RBBP9 was down-regulated after RA induction of differen-
tiation in H9 cells.
Treatment of human CA1 (ES) cells with siRNA against
RBBP4, RBBP9, or B2M showed that a loss of either
RBBP4 and RBBP9 was also associated with a significant
and specific decrease in the frequency of CFCs able to
form alkaline phosphatase-positive colonies, consistent
with a loss of their prior pluripotent status (Figs. 4C, 5C).
No change in cell or colony morphology was detected
with any siRNA treatment.
To determine whether reduced sequestration of RB
protein might be one of the consequences of reduced
RBBP4 and RBBP9 protein levels, we next asked whether
either actually binds RB in undifferentiated human PS cells.
Gels containing RB that had been immunoprecipitated
from NTera2D1 cell lysates gave 2 distinct bands (Fig. 6A)
corresponding to the expected sizes of hyper- and hypo-
phosphorylated RB protein [31–33]. Western blotting of
these preparations with specific antibodies against RBBP4
and RBBP9 showed both of these proteins had coprecipi-
tated with the RB protein (Fig. 6A).siRNA-mediated RBBP loss results in gene expression
changes indicative of differentiation
Treatment of NTera2D1 cells with siRNA to RBBP9
resulted in a significant reduction in FOXD3 expression
(Fig. 6B), whereas the siRNA-mediated decrease in RBBP4
caused a rapid and significant decrease in expression of
POU5F1, NANOG, SOX2, and FOXD3 (within 24 to 48
hours, Fig. 6C). The specificity of these effects was again
confirmed by their comparison to the lack of effects seen
in the same cells treated with siRNA to B2M, or the trans-
fection reagent alone (Fig. 6D).
To investigate accompanying changes in the expression
of other genes, Affymetrix analyses were performed on
RNA extracted from cells harvested 48 hours after being
treated with siRNAs for RBBP9 and 72 hours after being
treated with siRNAs for RBBP4 (or siRNAs for B2M as
a control). These times were selected to enable gene expres-
sion changes to be examined when the greatest effects on
known pluripotency genes had been seen. The results of
these Affymetrix analyses are presented in Supplementary
Figure E2 (online only, available at www.exphem.org).
Notably, RBBP4 and RBBP9 transcripts were among
Figure 4. Effect of RBBP9 siRNA treatment on undifferentiated and differentiating human PS cells. (A) Western blots of lysates from undifferentiated
human PS cells 48 hours after siRNA treatment. (B) Reduced numbers of undifferentiated and differentiating human EC (NTera2D1, NT), ES (CA1),
and iPS (MSC) cells detected 4 days after siRNA treatment as measured by Hoechst fluorescence. (C) CFC assays performed on human ES cells, and initiated
2 days after siRNA treatment, show reduced numbers of pluripotent cells detected after treatment with RBBP9 siRNA compared to B2M siRNA. Data shown
as mean 6 standard error of mean (p ! 0.05).
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scripts after RBBP siRNA treatment. Comparison of the
overall effects of these siRNA treatments showed that
approximately 10% of the genes whose expression increased
after loss of RBBP4 and RBBP9 were shared. A similar
degree of overlap was seen with the genes whose expression
was induced to decrease. Level 5 GO analysis performed on
the genes whose expression decreased after loss of RBBP4
showed an enrichment for genes involved in RNA processes
and processing (p 5 9.4  1010 to 0.0018), and also in
genes involved in cell cycle control, including well-known
cell cycle regulators (p 5 0.0028 and 0.0048; Table 1).
Similarly, genes whose expression decreased when RBBP9
was reduced were associated with RNA and protein metab-
olism (p 5 2.7  108 to 0.033), as well as cell cycle-
related processes (p 5 0.0049 and 0.006; Table 2). These
analyses also confirmed that NANOG was among the most
highly down-regulated genes after RBBP4 siRNA treatment,
and FOXD3 was similarly highly down-regulated after
RBBP9 siRNA treatment.Conversely, GO analysis of the genes whose expression
increased after loss of RBBP4 showed an enrichment for
genes involved in the regulation of GTPases (p 5
0.00034), protein modification, and protein metabolic
processes (p 5 0.0058 to 0.048), and also in genes
involved in nerve development (e.g., EPHB1, EPHB2,
FYN, SEMA3F, SEMA4D, SLIT2, and SMAD2, Table 1).
GO analysis of the genes whose expression increased after
loss of RBBP9 showed an enrichment for genes involved in
transcriptional regulation (p 5 6.6  104 to 4.4  102),
plus genes involved in organ morphogenesis and tissue
development (p 5 8  104 to 0.044; Supplementary
Figure E2; online only, available at www.exphem.org In
particular, this included genes involved in neurogenesis
(e.g. EFNB3, EPHB1, NEUROD4, NEUROG3,
NOTCH3, OLIG1, OLIG2, PAX6, and RUNX3; p 5 8 
104 to 0.034, Table 2). Notably among these
neurogenesis-related genes, increased expression of
EPHB1 was common to both RBBP4 and RBBP9 siRNA
treatments.
Figure 5. Effect of RBBP4 siRNA treatment on undifferentiated human PS cells. (A)Western blots of lysates from undifferentiated human PS cells 72 hours
after siRNA treatment. (B) Reduced numbers of undifferentiated human EC (NTera2D1, NT), ES (CA1), and iPS (MSC) cells, as measured by Hoechst
fluorescence, 4 days after initiating the siRNA treatment, without a significant effect on differentiating cells. (C) CFC assays performed on human ES cells,
and initiated 2 days after siRNA treatment, show reduced numbers of pluripotent cells detected after treatment with RBBP4 siRNA compared to B2M siRNA.
Data shown as mean 6 standard error of mean (p ! 0.05).
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and RBBP9
Finally, we again used PASTAA distal and proximal
analyses to investigate transcription factors that might
be involved in mediating the gene expression changes
seen after treatment of NTera2D1 cells with siRNAs to
RBBP4 and RBBP9. Both E2F and ATF motifs were among
the top PWMs predicted in the distal and/or proximal
regions of both the up- and down-regulated genes in both
treatment groups, including those genes whose expression
was commonly up- or down-regulated in the 2 groups
(Supplementary Table E6; online only, available at www.
exphem.org).
We then repeated an interrogation of the same ChIP data
analyzed above to determine whether in undifferentiated
human PS cells, E2Fs were bound to the promoters of genes
whose expression increased after treatment with siRNAs to
RBBP4 or RBBP9. To do this, we focused on genes involved
in neurogenesis, as we had found these to be commonlyup-regulated after siRNA-mediated loss of either RBBP.
The ChIP data showed no evidence of differential E2F1 or
E2F4 binding in the PS cells compared to four nonpluripo-
tent cell types for any of the seven neurogenesis genes exam-
ined whose expression increased after RBBP4 siRNA
treatment. For E2F6, binding at the promoters of three of
these seven genes (EPHB1, SEMA4D, and SLIT2) was noted
in the ChIP data for the pluripotent cells (Supplementary
Table E5; online only, available at www.exphem.org). The
ChIP data also showed no differential binding of E2F1 to
the promoters of any of the nine neurogenesis genes exam-
ined whose expression increased after RBBP9 siRNA treat-
ment. Similarly, E2F4 was differentially bound to the
promoter of only one of these nine genes (OLIG2) in PS
cells. For E2F6, binding at the promoters of four of these
nine genes (EPHB1, EFNB3, NEUROG3, OLIG2, see
Supplementary Table E5; online only, available at www.
exphem.org) was noted in the ChIP data for the PS cells
compared to the four non-pluripotent cell types.
Figure 6. RBBP4/9 associate with RB and regulate human PS cell gene expression. (A) RBBP4 and RBBP9 co-immunoprecipitate with RB. (B) RBBP9
siRNA treatment decreases FOXD3 expression after 48 hours. (C) RBBP4 siRNA treatment decreases FOXD3, NANOG, POU5F1, and SOX2 expression
after 72 hours. (D) B2M siRNA, but not RBBP4 siRNA, decreases B2M expression. Data shown as mean 6 standard error of mean (p ! 0.05).
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Here, we demonstrate the utility of high-resolution tran-
scriptome analyses together with bioinformatics and siRNA
screens to discover candidate new regulators of the plurip-
otent state of human EC, ES, and iPS cells. These methods,
both individually and in combination, consistently identi-
fied previously known critical pluripotency genes including
POU5F1, NANOG, SOX2, and ZIC3 [1–6,34,35]. The
detection of IL6ST and BIRC5 (i.e., SURVIVIN) provides
further evidence of the biological relevance of the siRNA
strategy used, as a signaling pathway involving IL6ST
has been shown to be functional in NTera2D1 cells [36],
and BIRC5 is required for teratoma formation by human
ES cells [37]. Further examination of the other genes
identified will help to discriminate those that participate
in regulatory networks that are shared by all types of human
PS cells. On the other hand, candidates that prove to be
required only by EC cells may provide novel information
about pathways important in tumor biology. Some of the
genes identified here may also be useful in somatic cell
reprogramming protocols, as suggested by the demon-
strated reprogramming activities of NANOG, POU5F1,
and Nr5a2 [10], genes which were all identified as regu-
lating human PS cells in the present study.Of particular interest is the evidence we obtained indi-
cating a key role of two RB-binding proteins, RBBP4 and
RBBP9, in the maintenance of all three types of human
PS cells studied. Affymetrix analysis, real-time PCR, and
Western blotting showed the RBBP siRNA treatments
caused specific, rapid, and significant decreases in the
targeted mRNAs and proteins. This coincided with a signif-
icant decrease in cell turnover and/or cell adhesion and
viability. PS cells are known to share a characteristically
short cell cycle and high rate of proliferation, which are
both affected by differentiation stimuli [29]. Consistent
with this, RBBP9 expression in rat liver epithelial cells leads
to a hyperproliferative state (due to its ability to sequester
RB from RB/E2F1 complexes, thus releasing free/active
E2F1 to stimulate cell cycle progression) [38]. The
decreased cell numbers obtained as a result of reducing
RBBP4 and RBBP9 expression are thus consistent with
the disruption of a complex shared network that links main-
tenance of pluripotency with a specific program for control-
ling the cell cycle progression of PS cells. The ability to
generate colonies of alkaline phosphatase-positive cells in
low-density cultures (CFC assay) is another characteristic
feature of pluripotent human ES and iPS cells that is rapidly
lost when these cells begin to differentiate [16]. Notably,
Table 1. GO analysis of genes with altered expression after RBBP4
siRNA treatment
Decreases with RBBP4 siRNA:
GO biological process level 5
‘‘M phase of mitotic cell cycle’’
(p 5 0.0028)
Increases with RBBP4 siRNA:
GO biological process level 5


























Table 2. GO analysis of genes with altered expression after RBBP9
siRNA treatment
Decreases with RBBP9 siRNA:
GO biological process level 5
‘‘mitosis’’ (p 5 0.0049)
Increases with RBBP9 siRNA
GO biological process level 5 ‘‘


























877M.D. O’Connor et al./ Experimental Hematology 2011;39:866–879forced reduction of RBBP4 and RBBP9 expression caused
a rapid and significant decrease in CFC frequency for
human ES and iPS cells.
The Affymetrix and real-time PCR data presented here
demonstrated that the cells present after RBBP4 and
RBBP9 siRNA treatments had significantly reduced levels
of core pluripotency gene transcripts (particularly NANOG
following RBBP4 siRNA treatment, and FOXD3 following
RBBP9 siRNA treatment). Treatment with RBBP4 and
RBBP9 siRNA also decreased expression of cell cycle
genes, including some known to be regulated by E2F tran-
scription factors (e.g., CCNA2 and CCNB1). Additionally,
loss of RBBP4 and RBBP9 was associated with increased
expression of multiple differentiation regulators, particu-
larly those involved in neurogenesis (e.g., EPHB1,
EPHB2, FYN, SEMA3F, SEMA4D, SLIT2, SMAD2 after
treatment with RBBP4 siRNA, and EPHB1, EFNB3, NEU-
ROD4, NEUROG3, NOTCH3, OLIG1, OLIG2, PAX6,
RUNX3 after treatment with RBBP9 siRNA). Taken
together, these findings suggest that maintained expression
of both RBBP4 and RBBP9 facilitates human PS cell
maintenance by promoting or permitting expression of
a combination of known pluripotency genes and cell cycle
regulators, and by inhibiting expression of genes required
for induction and propagation of specific differentiation
programs.The present studies also provide several lines of
evidence that the roles of RBBP4 and RBBP9 in maintain-
ing human PS cells may be mediated, at least in part,
through interactions with the RB-E2F pathway that is
known to control cell cycle progression [30], differentiation
programs in various cell types including mouse and human
ES cells [39–42], and somatic cell reprogramming [42].
Both RB-binding proteins can bind RB [38,43], as shown
here for NTera2D1 cells. Bioinformatic data presented
here and elsewhere [44–46] predicted E2F motifs to be
present within the promoters of core pluripotency regula-
tors, as well as a large number of other genes expressed
in PS cells or early differentiating cells. Moreover, the
promoters of genes whose expression was altered in PS
cells treated with RBBP4 or RBBP9 siRNAs also contained
E2F motifs, suggesting involvement of E2F factors as
mediators of these effects.
Traditionally, E2F1 has been viewed as a transcriptional
activator of cell cycle genes, whereas E2F4 and E2F6 are
viewed as transcriptional repressors (E2F6 acting in an
RB-independent manner). Inactivation of E2F1 or activation
of E2F4, both of which could occur as a result of RB release
after loss of RBBP4 or RBBP9, could thus conceivably
result in decreased transcription of pluripotency genes. In
support of this concept, we found that a number of genes
known to be regulated by E2F transcription factors
878 M.D. O’Connor et al./ Experimental Hematology 2011;39:866–879(e.g., CCNA2, CCNB1) showed decreased expression in
PS cells treated with RBBP4 siRNAs. Additional insights
were provided by analysis of published ChIP data. These
confirmed selective binding of E2F1, E2F4, and E2F6 to
the promoters of NANOG, POU5F1, SOX2, and FOXD3
in human ES and EC cells, but not in four separate nonplur-
ipotent cell lines [27,28]. Strikingly, in the same compar-
ison, the PS cells showed no preferential binding of
E2F1 to the promoters of any of the 15 neurogenesis genes
examined whose expression increased after RBBP siRNA
treatment. Similarly, for only one of these genes was E2F4
preferentially enriched at the promoter in PS cells, whereas
the RB-independent E2F6 was enriched at 6 of the 15 gene
promoters in PS cells compared to nonpluripotent cells.
For genes whose expression increased after RBBP siRNA
treatment, it is conceivable that RB release could activate
ATF transcription factors to increase gene expression
(via the ATF motifs identified here in their promoters),
analogous to that shown for RB and ATF2 increasing
TGF-b2 expression [47].
It is likely, however, that the consequences of RBBP4 and
RBBP9 siRNA treatments involve more complex mecha-
nistic changes that have many differences as well as some
similarities. The fact that only about 10% of the genes
with altered expression after RBBP4 and RBBP9 siRNA
were shared underscores this possibility, in spite of the
different treatment times used to generate Affymetrix
profiles (i.e., 48 hours after addition of the RBBP9 siRNAs
and 72 hours after addition of the RBBP4 siRNAs). Addi-
tional mechanisms could include the known involvement
of RBBP4 in NuRD and/or PRC2 complexes [48,49], both
of which have been implicated in PS cell function [50,51],
or through a recently identified serine hydrolase activity of
RBBP9 [52]. Taken together, these findings strongly support
the hypothesis that RBBP4 and RBBP9 play non-redundant
and essential roles in maintaining the regulatory programs
that define human PS cells. The present study sets the stage
for future investigations aimed at defining the molecular
mechanisms of RBBP4 and RBBP9 action in pluripotency
maintenance, the initiation of differentiation and, poten-
tially, somatic cell reprogramming.Acknowledgments
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